Azenosertib Readout Is a Make-or-Break Moment for Zentalis - Tactical Long Ahead of H1 '27 Data
Zentalis (ZNTL) is a clinical-stage oncology company advancing azenosertib, a first-in-class oral WEE1 inhibitor. With a clinical readout expected in H1 2027 that should materially re-rate the stock either way, this trade idea lays out a long-biased, risk-managed plan: enter near current levels, use a fairly wide stop to tolerate trial noise, and t…